We demonstrate preclinical synergy of telaglenastat (CB-839), a selective GLS inhibitor, when combined with azacytidine (AZA), <i>in vitro</i> and <i>in vivo</i>, followed by a phase Ib/II study of the combination in patients with advanced MDS. Here, GLS is linked to myelodysplastic syndrome.